GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applic
Genzyme announced today that it has filed a lawsuit in the District Court of Tel Aviv alleging that Transkaryotic Therapies Inc. has infringed Genzyme's Israeli patent No. 100,715, which covers certai
Measuring the quantity of a certain type of immune cell DNA in the blood could help physicians predict whether a bone marrow stem cell transplant will successfully restore a population of infection-fighting cells called T lymphocytes in a child. This r
The Australian APEC Study Centre has released a report showing how proposals for a patent-based regime to regulate access to genetic resources could inhibit efforts to protect biodiversity and undermi
GenoMed has filed a patent application on two additional genes linked to common cancers. These genes are the third and fourth identified as a result of GenoMed's research in 2005 to date. They have
ALDA Pharmaceuticals has filed national patent applications in the United States, Canada and Singapore for the formulation and production of Viralex. Last April, ALDA received a favourable in
ViaCell and Genzyme Corporation announced today that the two companies entered into a collaboration related to diabetes. Over the next 18
Vasogen today announced that it has been granted a European patent covering the use of its Celacade technology for the treatment of chronic heart failure, and has completed the registration procedure
Wyeth responded to the ruling today by the U.S. Court of Appeals for the Federal Circuit in the case of Israel Bio-Engineering Project v. Amgen, Inc. The Court reversed a previous summary judgment rulin
ParAllele BioScience has announced the issuance by the U.S. Patent Office of a key patent (6,858,412) covering its Molecular Inversion Probe (MIP) technology. The patent is owned by Stanford Univ
Date: Monday, 5-Feb-2007
Odyssey Thera announced today that on January 9, 2007, the United States Patent and Trademark Office granted U.S. Patent No. 7,160,691. On January 23, 2007, the USPTO also granted U.S. Patent No. 7,166,424.The invention covered by US 7,160,691 protects Protein-fragment Complementation Assays (PCAs) based on fragments of luminescent proteins. These assays exploit the wide dynamic range and signal-to-background ratios that are the hallmarks of luciferase assays, making them ideal for in vivo applications. The invention covered by US 7,166,424 broadly covers PCAs based on fragments of fluorescent proteins, including assays with diverse and improved spectral characteristics. Fluorescence-based PCAs are the foundation of Odyssey Thera's cell-based high-content assay panel -- the largest such capability in the world.
"These patents extend our already broad coverage of PCA technology," said John K. Westwick, Ph.D., Odyssey Thera President and CSO. "They solidify Odyssey Thera's leadership position in cellular analysis and further protect the use of these strategies in live animal studies."
http://www.odysseythera.com